The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Hy's law: predicting serious hepatotoxicity
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Multiple studies have also demonstrated that patients with higher total bilirubin and INR levels as well as lower serum albumin levels at presentation are at greatest risk for adverse outcomes.143–146”
From AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury (2023) · cites this paper as [145]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reuben, A. (2004) · Hepatology · doi:10.1002/hep.20081 · Cited by 190
Hepatic Findings in Long-Term Clinical Trials of Ximelagatran
Lee, W. M., Larrey, D., Olsson, R., Lewis, J. H., Keisu, M., Auclert, L., & Sheth, S. (2005) · Drug Safety · doi:10.2165/00002018-200528040-00006 · Cited by 189
Goldkind, L., & Laine, L. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1207 · Cited by 178
Cited by
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Coleman, R. L., Oza, A. M., Lorusso, D., Aghajanian, C., Oaknin, A., Dean, A., Colombo, N., Weberpals, J. I., Clamp, A., Scambia, G., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32440-6 · Cited by 1,693
EASL Clinical Practice Guidelines: Drug-induced liver injury
Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.014 · Cited by 1,276
Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury
Chalasani, N. P., Hayashi, P. H., Bonkovsky, H. L., Navarro, V. J., Lee, W. M., & Fontana, R. J. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.131 · Cited by 860
Drug-induced liver injury—types and phenotypes
Hoofnagle, J. H., & Björnsson, E. S. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1816149 · Cited by 652
Cortes, J. E., Heidel, F. H., Hellmann, A., Fiedler, W., Smith, B. D., Robak, T., Montesinos, P., Pollyea, D. A., DesJardins, P., Ottmann, O., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0312-9 · Cited by 496
Cellular Imaging Predictions of Clinical Drug-Induced Liver Injury
Xu, J. J., Henstock, P. V., Dunn, M. C., Smith, A. R., Chabot, J. R., & de Graaf, D. (2008) · Toxicological Sciences · doi:10.1093/toxsci/kfn109 · Cited by 492
ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury
Chalasani, N. P., Maddur, H., Russo, M. W., Wong, R. J., Reddy, K. R., & on behalf of the Practice Parameters Committee of the American College of Gastroenterology (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001259 · Cited by 430
FDA-approved drug labeling for the study of drug-induced liver injury
Chen, M., Vijay, V., Shi, Q., Liu, Z., Fang, H., & Tong, W. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.05.007 · Cited by 406
Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer
Monk, B. J., Herzog, T. J., Kaye, S. B., Krasner, C. N., Vermorken, J. B., Muggia, F. M., Pujade-Lauraine, E., Lisyanskaya, A. S., Makhson, A. N., Rolski, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4037 · Cited by 395
A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury
Singer, J. B., Lewitzky, S., Leroy, E., Yang, F., Zhao, X., Klickstein, L., Wright, T. M., Meyer, J., & Paulding, C. A. (2010) · Nature Genetics · doi:10.1038/ng.632 · Cited by 388
Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
Comi, G., Jeffery, D., Kappos, L., Montalban, X., Boyko, A., Rocca, M. A., & Filippi, M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1104318 · Cited by 364
Challenges and opportunities in NASH drug development
Harrison, S. A., Allen, A. M., Dubourg, J., Noureddin, M., & Alkhouri, N. (2023) · Nature Medicine · doi:10.1038/s41591-023-02242-6 · Cited by 353
Ubrogepant for the Treatment of Migraine
Dodick, D. W., Lipton, R. B., Ailani, J., Lu, K., Finnegan, M., Trugman, J. M., & Szegedi, A. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813049 · Cited by 349
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Fontana, R. J., Liou, I., Reuben, A., Suzuki, A., Fiel, M. I., Lee, W., & Navarro, V. (2023) · Hepatology · doi:10.1002/hep.32689 · Cited by 340
Ray, K. K., Troquay, R. P. T., Visseren, F. L. J., Leiter, L. A., Scott Wright, R., Vikarunnessa, S., Talloczy, Z., Zang, X., Maheux, P., Lesogor, A., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00353-9 · Cited by 328
Fontana, R. J., Seeff, L. B., Andrade, R. J., Björnsson, E., Day, C. P., Serrano, J., & Hoofnagle, J. H. (2010) · Hepatology · doi:10.1002/hep.23696 · Cited by 324
Atogepant for the Preventive Treatment of Migraine
Ailani, J., Lipton, R. B., Goadsby, P. J., Guo, H., Miceli, R., Severt, L., Finnegan, M., & Trugman, J. M. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035908 · Cited by 312
Idiosyncratic Adverse Drug Reactions: Current Concepts
Uetrecht, J., & Naisbitt, D. J. (2013) · Pharmacological Reviews · doi:10.1124/pr.113.007450 · Cited by 310
The future of drug safety testing: expanding the view and narrowing the focus
Stevens, J. L., & Baker, T. K. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.11.009 · Cited by 286
Lipton, R. B., Dodick, D. W., Ailani, J., Lu, K., Finnegan, M., Szegedi, A., & Trugman, J. M. (2019) · JAMA · doi:10.1001/jama.2019.16711 · Cited by 279
Mechanisms of drug-induced liver injury: from bedside to bench
Tujios, S., & Fontana, R. J. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.22 · Cited by 277
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Kappos, L., Wiendl, H., Selmaj, K., Arnold, D. L., Havrdova, E., Boyko, A., Kaufman, M., Rose, J., Greenberg, S., Sweetser, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501481 · Cited by 265
Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis
Kolb, M., Raghu, G., Wells, A. U., Behr, J., Richeldi, L., Schinzel, B., Quaresma, M., Stowasser, S., & Martinez, F. J. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1811737 · Cited by 264
Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention
Ho, T. W., Connor, K. M., Zhang, Y., Pearlman, E., Koppenhaver, J., Fan, X., Lines, C., Edvinsson, L., Goadsby, P. J., & Michelson, D. (2014) · Neurology · doi:10.1212/wnl.0000000000000771 · Cited by 262
Drug-induced Acute Liver Failure
Lee, W. M. (2013) · Clinics in Liver Disease · doi:10.1016/j.cld.2013.07.001 · Cited by 257
Drug-induced autoimmune-like hepatitis
Czaja, A. J. (2011) · Digestive Diseases and Sciences · doi:10.1007/s10620-011-1611-4 · Cited by 235
Devarbhavi, H., Dierkhising, R., Kremers, W. K., Sandeep, M. S., Karanth, D., & Adarsh, C. K. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.287 · Cited by 195
Features of autoimmune hepatitis in patients with drug-induced liver injury
de Boer, Y. S., Kosinski, A. S., Urban, T. J., Zhao, Z., Long, N., Chalasani, N., Kleiner, D. E., & Hoofnagle, J. H. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.05.043 · Cited by 190
Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines
Devarbhavi, H., Aithal, G., Treeprasertsuk, S., Takikawa, H., Mao, Y., Shasthry, S. M., Hamid, S., Tan, S. S., Philips, C. A., George, J., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10144-3 · Cited by 181
Kapitza, C., Nosek, L., Jensen, L., Hartvig, H., Jensen, C. B., & Flint, A. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.443 · Cited by 175
BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety
Fox, R. J., Kita, M., Cohan, S. L., Henson, L. J., Zambrano, J., Scannevin, R. H., O'Gorman, J., Novas, M., Dawson, K. T., & Phillips, J. T. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.849236 · Cited by 124
Stine, J. G., & Lewis, J. H. (2016) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1127756 · Cited by 104
HLA‐B*35:01 and Green Tea–Induced Liver Injury
Hoofnagle, J. H., Bonkovsky, H. L., Phillips, E. J., Li, Y., Ahmad, J., Barnhart, H., Durazo, F., Fontana, R. J., Gu, J., Khan, I., et al. (2021) · Hepatology · doi:10.1002/hep.31538 · Cited by 98
Krauskopf, J., Caiment, F., Claessen, S. M., Johnson, K. J., Warner, R. L., Schomaker, S. J., Burt, D. A., Aubrecht, J., & Kleinjans, J. C. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfu232 · Cited by 93
Lucena, M. I., Kaplowitz, N., Hallal, H., Castiella, A., García-Bengoechea, M., Otazua, P., Berenguer, M., Fernandez, M. C., Planas, R., & Andrade, R. J. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.12.041 · Cited by 89
Devarbhavi, H., Joseph, T., Sunil Kumar, N., Rathi, C., Thomas, V., Prasad Singh, S., Sawant, P., Goel, A., Eapen, C. E., Rai, P., et al. (2021) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2020.11.002 · Cited by 87
Vuppalanchi, R., Caldwell, S. H., Pyrsopoulos, N., deLemos, A. S., Rossi, S., Levy, C., Goldberg, D. S., Mena, E. A., Sheikh, A., Ravinuthala, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.08.025 · Cited by 79
Tang, F., Kunder, R., Chu, T., Hains, A., Nguyen, A., McBride, J. M., Zhong, Y., Santagostino, S., Wilson, M., Trenchak, A., et al. (2023) · Clinical and Translational Science · doi:10.1111/cts.13576 · Cited by 70
Muller, P. Y., & Dieterle, F. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250903114174 · Cited by 62
Drug induced liver injury: East versus West – a systematic review and meta-analysis
Low, E. X. S., Zheng, Q., Chan, E., & Lim, S. G. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2019.1003 · Cited by 45
Ou, P., Chen, Y., Li, B., Zhang, M., Liu, X., Li, F., Li, Y., Chen, C., Mao, Y., & Chen, J. (2015) · SpringerPlus · doi:10.1186/s40064-015-1600-8 · Cited by 28
Serum biomarkers of drug‐induced liver injury: Current status and future directions
Church, R. J., & Watkins, P. B. (2019) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12684 · Cited by 27
Buness, A., Roth, A., Herrmann, A., Schmitz, O., Kamp, H., Busch, K., & Suter, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097249 · Cited by 26
Drug-mediated toxicity: illuminating the ‘bad’ in the test tube by means of cellular assays?
Tralau, T., & Luch, A. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.03.015 · Cited by 24
Yang, H., Guo, D., Xu, Y., Zhu, M., Yao, C., Chen, C., & Jia, W. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00816 · Cited by 23
Trends in reporting drug-associated liver injuries in Taiwan: a focus on amiodarone
Ye, J.-H., Ho, Y.-F., On, A. W.-F., Chen, W.-W., Huang, Y.-M., Huang, W.-I., & Tang, Y.-W. (2018) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-018-0698-5 · Cited by 10
Liu, Y., Zhan, S.-P., Song, L., Chen, Y., Jia, Y.-T., Liu, F., Sun, F.-J., Wang, Q., & Xia, P.-Y. (2020) · Medical Science Monitor · doi:10.12659/msm.919435 · Cited by 6
Metadata
- Authors
- Temple, R.
- Venue
- Pharmacoepidemiology and Drug Safety
- Publisher
- Wiley
- Published
- 2006-03-22
- Volume
- 15
- Issue
- 4
- Pages
- 241-243
- ISSN
- 1053-8569 (ISSN-L)
- 1099-1557
- OpenAlex
- W2168198006
- Cited by
- 352
- References
- 3
- FWCI
- 6.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.